|
Volumn 33, Issue 7-8, 2001, Pages 3256-3258
|
The efficacy and safety of mizoribine in living donor kidney transplantation: A 24-week, open-label, prospective study (Phase III clinical trial)
a a a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
AZATHIOPRINE;
CYCLOSPORIN A;
MIZORIBINE;
PREDNISOLONE;
ALBUMIN BLOOD LEVEL;
AMINOTRANSFERASE BLOOD LEVEL;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CREATININE BLOOD LEVEL;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG SAFETY;
DRUG WITHDRAWAL;
GRAFT SURVIVAL;
HEMOGLOBIN DETERMINATION;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
INCIDENCE;
KIDNEY ALLOGRAFT REJECTION;
LEUKOCYTE COUNT;
LEUKOPENIA;
LIVING DONOR;
MAJOR CLINICAL STUDY;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RECIPIENT;
UREA NITROGEN BLOOD LEVEL;
AZATHIOPRINE;
CREATININE;
CYCLOSPORINE;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
LIVING DONORS;
PREDNISONE;
PROSPECTIVE STUDIES;
RIBONUCLEOSIDES;
SAFETY;
|
EID: 0035671387
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(01)02383-1 Document Type: Article |
Times cited : (7)
|
References (17)
|